Tarsus Pharmaceuticals (NASDAQ:TARS – Get Free Report) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, earnings and valuation.
Valuation & Earnings
This table compares Tarsus Pharmaceuticals and Adaptive Biotechnologies”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tarsus Pharmaceuticals | $17.45 million | 98.21 | -$135.89 million | ($3.81) | -11.77 |
| Adaptive Biotechnologies | $170.28 million | 4.40 | -$225.25 million | ($1.34) | -3.79 |
Tarsus Pharmaceuticals has higher earnings, but lower revenue than Adaptive Biotechnologies. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Profitability
This table compares Tarsus Pharmaceuticals and Adaptive Biotechnologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tarsus Pharmaceuticals | -103.64% | -55.86% | -39.28% |
| Adaptive Biotechnologies | -110.13% | -62.06% | -26.82% |
Analyst Recommendations
This is a summary of recent ratings for Tarsus Pharmaceuticals and Adaptive Biotechnologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tarsus Pharmaceuticals | 0 | 1 | 5 | 1 | 3.00 |
| Adaptive Biotechnologies | 0 | 1 | 3 | 0 | 2.75 |
Tarsus Pharmaceuticals presently has a consensus target price of $54.20, suggesting a potential upside of 20.90%. Adaptive Biotechnologies has a consensus target price of $6.50, suggesting a potential upside of 27.95%. Given Adaptive Biotechnologies’ higher possible upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Tarsus Pharmaceuticals.
Insider & Institutional Ownership
90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Tarsus Pharmaceuticals beats Adaptive Biotechnologies on 8 of the 14 factors compared between the two stocks.
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient’s body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
